Valuation: Replimune Group, Inc.

Market Cap 1.39B 1.19B 1.12B 1.02B 1.92B 133B 1.94B 13.18B 5.14B 66.89B 5.23B 5.11B 221B P/E 2027 *
-5.2x
P/E 2028 * -6.33x
Enterprise Value 1.31B 1.13B 1.05B 965M 1.81B 126B 1.83B 12.45B 4.85B 63.19B 4.94B 4.83B 209B EV / Sales 2027 *
29.7x
EV / Sales 2028 * 6.81x
Free-Float
98.3%
Yield 2027 *
-
Yield 2028 * -
1 day+5.12%
1 week-1.34%
Current month+31.88%
1 month+37.40%
3 months+200.81%
6 months+70.95%
Current year+51.95%
1 week 13.81
Extreme 13.81
15.64
1 month 4.76
Extreme 4.7648
15.7
Current year 1.5
Extreme 1.5
15.7
1 year 1.5
Extreme 1.5
15.7
3 years 1.5
Extreme 1.5
21.32
5 years 1.5
Extreme 1.5
35.93
10 years 1.5
Extreme 1.5
54.85
Manager TitleAgeSince
Chief Executive Officer 55 01/04/2024
Director of Finance/CFO 46 19/09/2023
Chief Tech/Sci/R&D Officer 60 01/12/2022
Director TitleAgeSince
Chairman 54 01/04/2024
Director/Board Member 66 01/07/2017
Chairman 65 01/04/2020
Date Insider Type Main position Quantity % Market Cap.
17/08/26 Sell

Chief Financial Officer

-9,256 0.0119%
11/08/26
Baker Bros. Advisors LP
BuyCompany 2,736,340 3.5056%
10/08/26 Sell

Controller/Auditor

-7,632 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
+5.12%-1.34%+160.49%-26.30% 1.39B
+1.09%+5.26%+4.52%+26.24% 51.61B
-1.07%+2.82%+465.96%+586.75% 44.89B
+1.47%+9.79%+35.92%+21.40% 42.77B
+1.44%+7.77%+19.38%+92.75% 42.58B
-0.93%-4.33%+16.18%+53.76% 31.82B
+1.32%+7.30%+33.89%+150.10% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+32.10% 14.76B
+1.28%+5.41%+82.40%+47.43% 14.09B
Average +0.92%+3.86%+91.70%+109.36% 27.79B
Weighted average by Cap. +0.51%+4.69%+99.90%+145.38%

Financials

2027 *2028 *
Net sales 44.29M 37.94M 35.5M 32.5M 60.99M 4.24B 61.79M 419M 164M 2.13B 166M 163M 7.04B 193M 165M 155M 142M 266M 18.48B 269M 1.83B 713M 9.28B 725M 710M 30.71B
Net income -291M -249M -233M -213M -400M -27.8B -405M -2.75B -1.07B -13.96B -1.09B -1.07B -46.19B -234M -200M -187M -171M -322M -22.35B -326M -2.21B -863M -11.23B -877M -858M -37.14B
Net Debt -77M -65.96M -61.72M -56.49M -106M -7.37B -107M -729M -284M -3.7B -289M -283M -12.24B -77M -65.96M -61.72M -56.49M -106M -7.37B -107M -729M -284M -3.7B -289M -283M -12.24B
Logo Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Employees
465
Date Price Change Volume
21/08/26 $14.77 +5.12% 2,969,475
20/08/26 $14.05 -5.13% 4,295,922
19/08/26 $14.81 -4.94% 3,441,404
18/08/26 $15.58 +6.49% 2,245,162
17/08/26 $14.63 -2.27% 3,735,001
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
14.77USD
Average target price
19.33USD
Spread / Average Target
+30.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REPL Stock